One can give all the twist to this but the fact remains that K is thrown under the bus.
If the results were so good - K would have moved much faster - it is clearly in back burner and may not even be mentioned in the next 10-q
K was Menon’s baby and his salary cut and his appearance from any company PR shows that K is not a key component
Rather than abandoning K in A single PR and raising concerns - he is taking slow approach - he clarified in PR today that you will hear about K till oral formulation is done and it is not a given. So no one can ask questions.
Remember gram negative compound and fox chase work - how it was dropped and then IP was given back?
You can say trial was not a failure - maybe. However as someone said this is the case of “ “ “OPERATION SUCCESSFUL PATIENT DIED”